Immunotherapy with tumor vaccines for the treatment of malignant gliomas

Current Drug Discovery Technologies

Volumn 9, Issue 4, 2012, Pages 237-255

  Ajay, Divya ^a,b   Sanchez Perez, Luis ^a   Choi, Bryan D ^a   De Leon, Gabriel ^a   Sampson, John H ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

Glioma; Immunotherapy; Vaccines

Indexed keywords

EID: 84868033440     PISSN: 15701638     EISSN: 18756220     Source Type: Journal    
DOI: 10.2174/157016312803305933     Document Type: Article

References (302)

1. Waldmann TA. Immunotherapy: past, present and future. Nat Med 2003; 9(3): 269-77. (Pubitemid 36362781)
2. Coley W. Further observations upon treatment of of malignant tumors with the toxins of erysipelas and bacillus prodigious with a report of 160 cases. Johns Hopkins Hospital Bulletin 1896; 7: 157-62.
3. Ehrlich P. On immunity with special reference to cell life: Croonian lecture. In: Himmelweir B, ed. The Collected Papers of Paul Ehrlich, Vol II: Immunology and Cancer Research. London, England: Pergammon; 1956. p. 148-92.
4. Patyar S, Joshi R, Byrav DS, Prakash A, Medhi B, Das BK. Bacteria in cancer therapy: a novel experimental strategy. J Biomed Sci 2010; 17(1): 21.
5. Ehrlich P. New York: John Wiley and Sons; 1906.
6. Hewitt HB, Blake ER, Walder AS. A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumours of spontaneous origin. Br J Cancer 1976; 33(3): 241-59.
7. Woglom WH. Immunity to transplantable tumors. Cancer Res 1929; 4(129).
8. [No authors listed]. Sipuleucel-T: APC 8015, APC-8015, Prostate Cancer Vaccine - Dendreon. Drugs R D 2006; 7(3): 197-201.
9. Cha E, Fong L. Therapeutic vaccines for prostate cancer. Curr Opin Mol Ther 2010; 12(1): 77-85.
10. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363(8): 711-23.
11. Morse MA, Whelan M. A year of successful cancer vaccines points to a path forward. Curr Opin Mol Ther 2010; 12(1): 11-3.
12. Stein WD, Gulley JL, Schlom J, et al. Tumor Regression and Growth Rates Determined in Five Intramural NCI Prostate Cancer Trials: The Growth Rate Constant as an Indicator of Therapeutic Efficacy. Clin Cancer Res 2011; 17(4): 907-17.
13. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 2001; 411(6835): 380-4. (Pubitemid 32467048)
14. Rosenberg SA. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 1999; 10(3): 281-7. (Pubitemid 29165283)
15. Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 1994; 12: 337-65. (Pubitemid 24140418)
16. van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254(5038): 1643-7. (Pubitemid 21917508)
17. Wong AJ, Ruppert JM, Bigner SH, et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci USA 1992; 89(7): 2965-9.
18. Choi BD, Archer GE, Mitchell DA, et al. EGFRvIII-targeted vaccination therapy of malignant glioma. Brain Pathol 2009; 19(4): 713-23.
19. Neal DE, Sharples L, Smith K, Fennelly J, Hall RR, Harris AL. The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer 1990; 65(7): 1619-25. (Pubitemid 20106125)
20. Chaffanet M, Chauvin C, Laine M, et al. EGF receptor amplification and expression in human brain tumours. Eur J Cancer 1992; 28(1): 11-7.
21. Moscatello DK, Holgado-Madruga M, Godwin AK, et al. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res 1995; 55(23): 5536-9.
22. Kawakami Y, Eliyahu S, Delgado CH, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 1994; 91(9): 3515-9. (Pubitemid 24139460)
23. Kawakami Y, Eliyahu S, Delgado CH, et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 1994; 91(14): 6458-62.
24. Brichard V, Van Pel A, Wolfel T, et al. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1993; 178(2): 489-95. (Pubitemid 23218197)
25. Wang RF, Robbins PF, Kawakami Y, Kang XQ, Rosenberg SA. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J Exp Med 1995; 181(2): 799-804.
26. Wang RF, Appella E, Kawakami Y, Kang XQ, Rosenberg SA. Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J Exp Med 1996; 184(6): 2207-16. (Pubitemid 27023721)
27. Salazar-Onfray F, Nakazawa T, Chhajlani V, et al. Synthetic peptides derived from the melanocyte-stimulating hormone receptor MC1R can stimulate HLA-A2-restricted cytotoxic T lymphocytes that recognize naturally processed peptides on human melanoma cells. Cancer Res 1997; 57(19): 4348-55. (Pubitemid 27413445)
28. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005; 5(8): 615-25. (Pubitemid 41081387)
29. Visseren MJ, van der Burg SH, van der Voort EI, et al. Identification of HLA-A*0201-restricted CTL epitopes encoded by the tumor-specific MAGE-2 gene product. Int J Cancer 1997; 73(1): 125-30. (Pubitemid 27447024)
30. Gaugler B, Van den Eynde B, van der Bruggen P, et al. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 1994; 179(3): 921-30. (Pubitemid 24065650)
31. Panelli MC, Bettinotti MP, Lally K, et al. A tumor-infiltrating lymphocyte from a melanoma metastasis with decreased expression of melanoma differentiation antigens recognizes MAGE-12. J Immunol 2000; 164(8): 4382-92. (Pubitemid 30215102)
32. Boel P, Wildmann C, Sensi ML, et al. BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 1995; 2(2): 167-75.
33. Vandeneynde B, Peeters O, Debacker O, Gaugler B, Lucas S, Boon T. A New Family of Genes-Coding for an Antigen Recognized by Autologous Cytolytic T-Lymphocytes on a Human-Melanoma. J Exp Med 1995; 182(3): 689-98.
34. Jager E, Chen YT, Drijfhout JW, et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: Definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. Journal of Experimental Medicine 1998; 187(2): 265-70. (Pubitemid 28060443)
35. Wang RF, Johnston SL, Zeng G, Topalian SL, Schwartzentruber DJ, Rosenberg SA. A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames. J Immunol 1998; 161(7): 3598-606.
36. Robbins PF, El-Gamil M, Li YF, et al. A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med 1996; 183(3): 1185-92.
37. Chiari R, Foury F, De Plaen E, Baurain JF, Thonnard J, Coulie PG. Two antigens recognized by autologous cytolytic T lymphocytes on a melanoma result from a single point mutation in an essential housekeeping gene. Cancer Res 1999; 59(22): 5785-92.
38. Wolfel T, Hauer M, Schneider J, et al. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995; 269(5228): 1281-4.
39. Mandruzzato S, Brasseur F, Andry G, Boon T, van der Bruggen P. A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma. J Exp Med 1997; 186(5): 785-93. (Pubitemid 27381543)
40. Gueguen M, Patard JJ, Gaugler B, et al. An antigen recognized by autologous CTLs on a human bladder carcinoma. J Immunol 1998; 160(12): 6188-94. (Pubitemid 28298085)
41. Brandle D, Brasseur F, Weynants P, Boon T, Van den Eynde B. A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma. J Exp Med 1996; 183(6): 2501-8. (Pubitemid 26192359)
42. Butterfield LH, Koh A, Meng W, et al. Generation of human T-cell responses to an HLA-A2.1-restricted peptide epitope derived from alpha-fetoprotein. Cancer Res 1999; 59(13): 3134-42. (Pubitemid 29316013)
43. Vonderheide RH, Hahn WC, Schultze JL, Nadler LM. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 1999; 10(6): 673-9. (Pubitemid 29302920)
44. Vissers JL, De Vries IJ, Schreurs MW, et al. The renal cell carcinoma-associated antigen G250 encodes a human leukocyte antigen (HLA)-A2.1-restricted epitope recognized by cytotoxic T lymphocytes. Cancer Res 1999; 59(21): 5554-9. (Pubitemid 29526473)
45. Jerome KR, Barnd DL, Bendt KM, et al. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res 1991; 51(11): 2908-16.
46. Tsang KY, Zaremba S, Nieroda CA, Zhu MZ, Hamilton JM, Schlom J. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst 1995; 87(13): 982-90.
47. Theobald M, Biggs J, Dittmer D, Levine AJ, Sherman LA. Targeting p53 as a general tumor antigen. Proc Natl Acad Sci USA 1995; 92(26): 11993-7. (Pubitemid 26013997)
48. Ioannides CG, Fisk B, Fan D, Biddison WE, Wharton JT, O'Brian CA. Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER-2/neu proto-oncogene. Cell Immunol 1993; 151(1): 225-34. (Pubitemid 23308446)
49. Li K, Adibzadeh M, Halder T, et al. Tumour-specific MHC-class-II- restricted responses after in vitro sensitization to synthetic peptides corresponding to gp100 and Annexin II eluted from melanoma cells. Cancer Immunol Immunother 1998; 47(1): 32-8. (Pubitemid 28430528)
50. Chaux P, Vantomme V, Stroobant V, et al. Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes. J Exp Med 1999; 189(5): 767-78.
51. Topalian SL, Rivoltini L, Mancini M, et al. Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc Natl Acad Sci USA 1994; 91(20): 9461-5. (Pubitemid 24297934)
52. Zeng G, Touloukian CE, Wang X, Restifo NP, Rosenberg SA, Wang RF. Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules. J Immunol 2000; 165(2): 1153-9. (Pubitemid 30484788)
53. Pieper R, Christian RE, Gonzales MI, et al. Biochemical identification of a mutated human melanoma antigen recognized by CD4(+) T cells. J Exp Med 1999; 189(5): 757-66.
54. Wang RF, Wang X, Atwood AC, et al. Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. Science 1999; 284(5418): 1351-4. (Pubitemid 29289659)
55. Wang RF, Wang X, Rosenberg SA. Identification of a novel major histocompatibility complex class II-restricted tumor antigen resulting from a chromosomal rearrangement recognized by CD4(+) T cells. J Exp Med 1999; 189(10): 1659-68.
56. Kuramoto T. Detection of MAGE-1 tumor antigen in brain tumor. Kurume Med J 1997; 44(1): 43-51. (Pubitemid 127510158)
57. Sasaki M, Nakahira K, Kawano Y, et al. MAGE-E1, a new member of the melanoma-associated antigen gene family and its expression in human glioma. Cancer Res 2001; 61(12): 4809-14. (Pubitemid 32691895)
58. Sahin U, Koslowski M, Tureci O, et al. Expression of cancer testis genes in human brain tumors. Clin Cancer Res 2000; 6(10): 3916-22.
59. Scarcella DL, Chow CW, Gonzales MF, et al. Expression of MAGE and GAGE in high-grade brain tumors: a potential target for specific immunotherapy and diagnostic markers. Clin Cancer Res 1999; 5(2): 335-41. (Pubitemid 29085187)
60. Ueda R, Yoshida K, Kawase T, Kawakami Y, Toda M. Preferential expression and frequent IgG responses of a tumor antigen, SOX5, in glioma patients. Int J Cancer 2007; 120(8): 1704-11. (Pubitemid 46399357)
61. Ueda R, Kinoshita E, Ito R, Kawase T, Kawakami Y, Toda M. Induction of protective and therapeutic antitumor immunity by a DNA vaccine with a glioma antigen, SOX6. Int J Cancer 2008; 122(10): 2274-9. (Pubitemid 351542331)
62. Okano F, Storkus WJ, Chambers WH, Pollack If, Okada H. Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain. Clin Cancer Res 2002; 8(9): 2851-5. (Pubitemid 35025729)
63. Hatano M, Eguchi J, Tatsumi T, et al. EphA2 as a gliomaassociated antigen: a novel target for glioma vaccines. Neoplasia 2005; 7(8): 717-22.
64. Liu G, Yu JS, Zeng G, et al. AIM-2: a novel tumor antigen is expressed and presented by human glioma cells. J Immunother 2004; 27(3): 220-6. (Pubitemid 39118086)
65. Imaizumi T, Kuramoto T, Matsunaga K, et al. Expression of the tumor-rejection antigen SART1 in brain tumors. Int J Cancer 1999; 83(6): 760-4.
66. Murayama K, Kobayashi T, Imaizumi T, et al. Expression of the SART3 tumor-rejection antigen in brain tumors and induction of cytotoxic T lymphocytes by its peptides. J Immunother 2000; 23(5): 511-8.
67. Harada M, Ishihara Y, Itoh K, Yamanaka R. Kinesin superfamily protein-derived peptides with the ability to induce glioma-reactive cytotoxic T lymphocytes in human leukocyte antigen-A24+ glioma patients. Oncol Rep 2007; 17(3): 629-36.
68. zur Hausen H. Human papillomaviruses in the pathogenesis of anogenital cancer. Virology 1991; 184(1): 9-13.
69. Hislop AD, Taylor GS, Sauce D, Rickinson AB. Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol 2007; 25: 587-617. (Pubitemid 46697918)
70. Mitchell DA, Xie W, Schmittling R, et al. Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro Oncol 2008; 10(1): 10-8. (Pubitemid 351250896)
71. Scheurer ME, Bondy ML, Aldape KD, Albrecht T, El-Zein R. Detection of human cytomegalovirus in different histological types of gliomas. Acta Neuropathol 2008; 116(1): 79-86.
72. Cobbs CS, Harkins L, Samanta M, et al. Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res 2002; 62(12): 3347-50. (Pubitemid 34651375)
73. Zhang B, Karrison T, Rowley DA, Schreiber H. IFN-gamma- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers. J Clin Invest 2008; 118(4): 1398-404. (Pubitemid 351500433)
74. Qin Z, Blankenstein T. CD4+ T cell - mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity 2000; 12(6): 677-86.
75. Briesemeister D, Sommermeyer D, Loddenkemper C, et al. Tumor rejection by local interferon gamma induction in established tumors is associated with blood vessel destruction and necrosis. Int J Cancer 2011; 128(2): 371-8.
76. Ranieri E, Kierstead LS, Zarour H, et al. Dendritic cell/peptide cancer vaccines: clinical responsiveness and epitope spreading. Immunol Invest 2000; 29(2): 121-5. (Pubitemid 30316952)
77. Schietinger A, Philip M, Liu RB, Schreiber K, Schreiber H. Bystander killing of cancer requires the cooperation of CD4(+) and CD8(+) T cells during the effector phase. J Exp Med 2010; 207(11): 2469-77.
78. Brossart P, Wirths S, Stuhler G, Reichardt VL, Kanz L, Brugger W. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 2000; 96(9): 3102-8.
79. Medawar P. Immunity to homologous grafted skin; the fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. Br J Exp Pathol 1948; 29(1): 12.
80. Wolburg H, Lippoldt A. Tight junctions of the blood-brain barrier: development, composition and regulation. Vascul Pharmacol 2002; 38(6): 323-37. (Pubitemid 36398254)
81. Parney IF, Hao C, Petruk KC. Glioma immunology and immunotherapy. Neurosurgery 2000; 46: 778-91.
82. Hart DN FJ. Demonstration and characterization of Ia-positive dendritic cells in the interstitial connective tissue of rat hearts and other tissue, but not brain. J Exp Med 1981; 154: 347-61.
83. Fabry Z RC, Hart MN. Nervous tissue as a immune compartment: the dialect of the immune response in the CNS. Immunol Today 1994; 15: 218-24. (Pubitemid 24137975)
84. Brent L, editor.: Elsevier Science Publishers; 1990.
85. Engelhardt B, Ransohoff RM. The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms. Trends Immunol 2005; 26(9): 485-95. (Pubitemid 41139258)
86. Cserr HE, Knopf PM. Cervical lymphatics, the blood-brain barrier and the immunoreactivity of the brain: a new view. Immunology today 1992; 13(2): 507-12.
87. Weller RO, Engelhardt B, Phillips MJ. Lymphocyte targeting of the central nervous system: A review of afferent and efferent CNS-immune pathways. Brain Pathology 1996; 6(3): 275-88. (Pubitemid 26246383)
88. J Germann YM, GW Kreutzberg. Microglia: intrinsic immunoeffector cell of the brain. Brain Res Review 1995; 20(3): 269-87.
89. Sehgal A, Berger MS. Basic concepts of immunology and neuroimmunology. Neurosurg Focus 2000; 9(6): e1.
90. Frei K, Fontana A. Antigen presentation in the CNS. Molecular Psychiatry 1997; 2: 96-8. (Pubitemid 27166020)
91. Freund J. Accumulation of Antibodies in the Central Nervous System. J Exp Med 1930; 51(6): 889-902.
92. Dalmau J, Rosenfeld MR. Paraneoplastic syndromes of the CNS. Lancet Neurol 2008; 7(4): 327-40. (Pubitemid 351380534)
93. Zalutsky MR, Moseley RP, Coakham HB, Coleman RE, Bigner DD. Pharmacokinetics and tumor localization of 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies. Cancer Res 1989; 49(10): 2807-13. (Pubitemid 19143420)
94. Scott AM, Lee FT, Tebbutt N, et al. A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. Proc Natl Acad Sci USA 2007; 104(10): 4071-6. (Pubitemid 47181580)
95. Hickey WF. Migration of hematogenous cells through the bloodbrain barrier and the initiation of CNS inflammation. Brain Pathol 1991; 1(2): 97-105.
96. Bullard DE, Gillespie GY, Mahaley MS, Bigner DD. Immunobiology of human gliomas. Semin Oncol 1986; 13(1): 94-109. (Pubitemid 16116044)
97. Wekerle H. Cellular immune reactivity within the CNS. Trends in Neurosciences 1986; 9: 271-7. (Pubitemid 16030829)
98. Masson F, Calzascia T, Di Berardino-Besson W, de Tribolet N, Dietrich PY, Walker PR. Brain microenvironment promotes the final functional maturation of tumor-specific effector CD8+ T cells. J Immunol 2007; 179(2): 845-53.
99. Ford AL, Foulcher E, Lemckert FA, Sedgwick JD. Microglia induce CD4 T lymphocyte final effector function and death. J Exp Med 1996; 184(5): 1737-45. (Pubitemid 26404465)
100. Goldmann J, Kwidzinski E, Brandt C, Mahlo J, Richter D, Bechmann I. T cells traffic from brain to cervical lymph nodes via the cribroid plate and the nasal mucosa. J Leukoc Biol 2006; 80(4): 797-801. (Pubitemid 44835898)
101. Pardoll DM. Spinning molecular immunology into successful immunotherapy. Nat Rev Immunol 2002; 2(4): 227-38. (Pubitemid 37323223)
102. Pejawar-Gaddy S, Finn OJ. Cancer vaccines: accomplishments and challenges. Crit Rev Oncol Hematol 2008; 67(2): 93-102.
103. Sjoblom T, Jones S, Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006; 314(5797): 268-74. (Pubitemid 44571966)
104. Forrest WF, Cavet G. Comment on "The consensus coding sequences of human breast and colorectal cancers". Science 2007; 317(5844): 1500; author reply
105. Hanna MG, Jr., Peters LC. Immunotherapy of established micrometastases with Bacillus Calmette-Guerin tumor cell vaccine. Cancer Res 1978; 38(1): 204-9. (Pubitemid 8253538)
106. Hanna MG, Jr., Bucana C. Active specific immunotherapy of residual micrometastasis: the acute and chronic inflammatory response in induction of tumor immunity by BCG-tumor cell immunization. J Reticuloendothel Soc 1979; 26(4): 439-51.
107. Sampson JH, Archer GE, Ashley DM, et al. Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system. Proc Natl Acad Sci USA 1996; 93(19): 10399-404.
108. Dranoff G. GM-CSF-based cancer vaccines. Immunol Rev 2002; 188: 147-54. (Pubitemid 35398872)
109. Dranoff G. GM-CSF-secreting melanoma vaccines. Oncogene 2003; 22(20): 3188-92. (Pubitemid 36713771)
110. Zarei S, Schwenter F, Luy P, et al. Role of GM-CSF signaling in cell-based tumor immunization. Blood 2009; 113(26): 6658-68.
111. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and longlasting anti-tumor immunity. Proc Natl Acad Sci USA 1993; 90(8): 3539-43. (Pubitemid 23111402)
112. Vermorken JB, Claessen AM, van Tinteren H, et al. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet 1999; 353(9150): 345-50. (Pubitemid 29088160)
113. Hoover HC, Jr., Brandhorst JS, Peters LC, et al. Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial. J Clin Oncol 1993; 11(3): 390-9. (Pubitemid 23071033)
114. Harris JE, Ryan L, Hoover HC, Jr., et al. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283. J Clin Oncol 2000; 18(1): 148-57. (Pubitemid 30036348)
115. Michael A, Ball G, Quatan N, et al. Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables. Clin Cancer Res 2005; 11(12): 4469-78. (Pubitemid 40825637)
116. Small EJ, Sacks N, Nemunaitis J, et al. Granulocyte macrophage colony-stimulating factor - secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res 2007; 13(13): 3883-91. (Pubitemid 47037595)
117. Simons JW, Carducci MA, Mikhak B, et al. Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naive prostate cancer. Clin Cancer Res 2006; 12(11 Pt 1): 3394-401.
118. Jocham D, Richter A, Hoffmann L, et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 2004; 363(9409): 594-9. (Pubitemid 38264176)
119. de Gruijl TD, van den Eertwegh AJ, Pinedo HM, Scheper RJ. Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines. Cancer Immunol Immunother 2008; 57(10): 1569-77.
120. Cheuk AT, Chan L, Czepulkowski B, et al. Development of a whole cell vaccine for acute myeloid leukaemia. Cancer Immunol Immunother 2006; 55(1): 68-75. (Pubitemid 41783296)
121. Cheuk AT, Guinn BA. Immunotherapy of acute myeloid leukaemia: development of a whole cell vaccine. Front Biosci 2008; 13: 2022-9. (Pubitemid 351606110)
122. Sloan AE, Dansey R, Zamorano L, et al. Adoptive immunotherapy in patients with recurrent malignant glioma: preliminary results of using autologous whole-tumor vaccine plus granulocytemacrophage colony-stimulating factor and adoptive transfer of anti-CD3-activated lymphocytes. Neurosurg Focus 2000; 9(6): e9.
123. Fakhrai H, Mantil JC, Liu L, et al. Phase I clinical trial of a TGF-beta antisense-modified tumor cell vaccine in patients with advanced glioma. Cancer Gene Ther 2006; 13(12): 1052-60. (Pubitemid 44760103)
124. Okada H, Lieberman FS, Walter KA, et al. Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas. J Transl Med 2007; 5: 67.
125. Okada H, Pollack IF, Lotze MT, et al. Gene therapy of malignant gliomas: a phase I study of IL-4-HSV-TK gene-modified autologous tumor to elicit an immune response. Hum Gene Ther 2000; 11(4): 637-53. (Pubitemid 30134307)
126. Dillman RO, Nayak SK, Beutel L. Establishing in vitro cultures of autologous tumor cells for use in active specific immunotherapy. J Immunother Emphasis Tumor Immunol 1993; 14(1): 65-9. (Pubitemid 23239942)
127. Logan TF, Shannon W, Bryant J, et al. Preparation of viable tumour cell vaccine from human solid tumours: relationship between tumour mass and cell yield. The Tissue Bank, Pittsburgh Cancer Institute. Melanoma Res 1993; 3(6): 451-5. (Pubitemid 24051368)
128. Bigner DD, Pitts OM, Wikstrand CJ. Induction of lethal experimental allergic encephalomyelitis in nonhuman primates and guinea pigs with human glioblastoma multiforme tissue. J Neurosurg 1981; 55(1): 32-42. (Pubitemid 11125467)
129. Vandenabeele S LL, Ashley D. Dendritic Cell Immunotherapy for Brain Tumors. In: LIAU LM BD, CLOUGHESY TF, BIGNER DD, editor. Brain Tumor Immunotherapy. New Jersey: Humana Press; 2001.
130. Srivastava PK. Immunotherapy for human cancer using heat shock protein-peptide complexes. Curr Oncol Rep 2005; 7(2): 104-8. (Pubitemid 40485465)
131. Srivastava PK. Immunotherapy of human cancer: lessons from mice. Nat Immunol 2000; 1(5): 363-6.
132. Binder RJ, Han DK, Srivastava PK. CD91: a receptor for heat shock protein gp96. Nat Immunol 2000; 1(2): 151-5.
133. Segal BH, Wang XY, Dennis CG, et al. Heat shock proteins as vaccine adjuvants in infections and cancer. Drug Discov Today 2006; 11(11-12): 534-40. (Pubitemid 43732542)
134. Tamura Y, Peng P, Liu K, Daou M, Srivastava PK. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 1997; 278(5335): 117-20. (Pubitemid 27446289)
135. Roman LD, Wilczynski S, Muderspach LI, et al. A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia. Gynecol Oncol 2007; 106(3): 558-66. (Pubitemid 47302472)
136. Belli F, Testori A, Rivoltini L, et al. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J Clin Oncol 2002; 20(20): 4169-80. (Pubitemid 35191019)
137. Mazzaferro V, Coppa J, Carrabba MG, et al. Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer. Clin Cancer Res 2003; 9(9): 3235-45. (Pubitemid 37082717)
138. Hermisson M, Strik H, Rieger J, Dichgans J, Meyermann R, Weller M. Expression and functional activity of heat shock proteins in human glioblastoma multiforme. Neurology 2000; 54(6): 1357-65.
139. Mocellin S, Mandruzzato S, Bronte V, Lise M, Nitti D. Part I: Vaccines for solid tumours. Lancet Oncol 2004; 5(11): 681-9. (Pubitemid 40267853)
140. Bhattacharya-Chatterjee M, Chatterjee SK, Foon KA. Anti-idiotype vaccine against cancer. Immunol Lett 2000; 74(1): 51-8.
141. Handgretinger R, Anderson K, Lang P, et al. A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma. Eur J Cancer 1995; 31A(2): 261-7.
142. Bhattacharya-Chatterjee M, Mrozek E, Mukerjee S, Ceriani RL, Kohler H, Foon KA. Anti-idiotype antibodies as potential therapeutic agents for human breast cancer. Adv Exp Med Biol 1994; 353: 139-48. (Pubitemid 24256921)
143. Robins RA, Denton GW, Hardcastle JD, Austin EB, Baldwin RW, Durrant LG. Antitumor immune response and interleukin 2 production induced in colorectal cancer patients by immunization with human monoclonal anti-idiotypic antibody. Cancer Res 1991; 51(19): 5425-9.
144. Kuan CT, Wikstrand CJ, Bigner DD. EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr Relat Cancer 2001; 8(2): 83-96. (Pubitemid 32641351)
145. Wikstrand CJ, Cole VR, Crotty LE, Sampson JH, Bigner DD. Generation of anti-idiotypic reagents in the EGFRvIII tumorassociated antigen system. Cancer Immunol Immunother 2002; 50(12): 639-52. (Pubitemid 34146569)
146. Yamanaka R. Dendritic-cell- and peptide-based vaccination strategies for glioma. Neurosurg Rev 2009; 32(3): 265-73; discussion 73.
147. Mitchell DA, Sampson JH. Toward effective immunotherapy for the treatment of malignant brain tumors. Neurotherapeutics 2009; 6(3): 527-38.
148. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998; 4(3): 321-7. (Pubitemid 28144091)
149. Rosenberg SA, Yang JC, Topalian SL, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 1994; 271(12): 907-13.
150. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10(9): 909-15. (Pubitemid 39273730)
151. Klebanoff CA, Acquavella N, Yu Z, Restifo NP. Therapeutic cancer vaccines: are we there yet? Immunol Rev 2011; 239(1): 27-44.
152. Moscatello DK, Ramirez G, Wong AJ. A naturally occurring mutant human epidermal growth factor receptor as a target for peptide vaccine immunotherapy of tumors. Cancer Res 1997; 57(8): 1419-24. (Pubitemid 27175553)
153. Heimberger AB, Crotty LE, Archer GE, et al. Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res 2003; 9(11): 4247-54. (Pubitemid 37204046)
154. Sampson JH, Archer GE, Mitchell DA, et al. An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Mol Cancer Ther 2009; 8(10): 2773-9.
155. Schmittling RJ, Archer GE, Mitchell DA, et al. Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines. J Immunol Methods 2008; 339(1): 74-81.
156. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352(10): 987-96. (Pubitemid 40349501)
157. Sampson JH, Archer GE, Bigner DD, et al. Effect of EGFRvIII-targeted vaccine (CDX-110) on immune response and TTP when given with simultaneous standard and continuous temozolomide in patients with GBM. J Clin Oncol 2011; 26(abstr 2011).
158. Sampson JH, Archer GE, Mitchell DA, Heimberger AB, Bigner DD. Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. Semin Immunol 2008; 20(5): 267-75.
159. Kanaly CW, Ding D, Heimberger AB, Sampson JH. Clinical applications of a peptide-based vaccine for glioblastoma. Neurosurg Clin N Am 2010; 21(1): 95-109.
160. Yajima N, Yamanaka R, Mine T, et al. Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma.
161. Izumoto S, Tsuboi A, Oka Y, et al. Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme. J Neurosurg 2008; 108(5): 963-71. (Pubitemid 351656845)
162. Liao SK, Clarke BJ, Kwong PC, Brickenden A, Gallic BL, Dent PB. Common neuroectodermal antigens on human melanoma, neuroblastoma, retinoblastoma, glioblastoma and fetal brain revealed by hybridoma antibodies raised against melanoma cells. Eur J Immunol 1981; 11(6): 450-4. (Pubitemid 11039845)
163. Rimoldi D, Romero P, Carrel S. The human melanoma antigenencoding gene, MAGE-1, is expressed by other tumour cells of neuroectodermal origin such as glioblastomas and neuroblastomas. Int J Cancer 1993; 54(3): 527-8. (Pubitemid 23169697)
164. Zhang JG, Eguchi J, Kruse CA, et al. Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell-based therapeutics. Clin Cancer Res 2007; 13(2 Pt 1): 566-75. (Pubitemid 46225363)
165. Zimmer C, Gottschalk J, Goebel S, Cervos-Navarro J. Melanomaassociated antigens in tumours of the nervous system: an immunohistochemical study with the monoclonal antibody HMB-45. Virchows Arch A Pathol Anat Histopathol 1992; 420(2): 121-6.
166. Soderberg-Naucler C. HCMV microinfections in inflammatory diseases and cancer. J Clin Virol 2008; 41(3): 218-23.
167. Prins RM, Cloughesy TF, Liau LM. Cytomegalovirus immunity after vaccination with autologous glioblastoma lysate. N Engl J Med 2008; 359(5): 539-41.
168. Mintz A, Debinski W. Cancer genetics/epigenetics and the X chromosome: possible new links for malignant glioma pathogenesis and immune-based therapies. Crit Rev Onco 2000; 11(1): 77-95. (Pubitemid 30220600)
169. Debinski W. An immune regulatory cytokine receptor and glioblastoma multiforme: an unexpected link. Crit Rev Oncog 1998; 9(3-4): 255-68. (Pubitemid 29102648)
170. Skog J. Glioma-specific antigens for immune tumor therapy. Expert Rev Vaccines 2006; 5(6): 793-802. (Pubitemid 46021057)
171. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 2007; 449(7161): 419-26. (Pubitemid 47509552)
172. Mosca PJ, Lyerly HK, Clay TM, Morse MA, Lyerly HK. Dendritic cell vaccines. Front Biosci 2007; 12: 4050-60.
173. Inaba K, Inaba M, Romani N, et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 1992; 176(6): 1693-702.
174. Mu LJ, Gaudernack G, Saeboe-Larssen S, Hammerstad H, Tierens A, Kvalheim G. A protocol for generation of clinical grade mRNAtransfected monocyte-derived dendritic cells for cancer vaccines. Scand J Immunol 2003; 58(5): 578-86. (Pubitemid 37430919)
175. Tuyaerts S, Noppe SM, Corthals J, et al. Generation of large numbers of dendritic cells in a closed system using Cell Factories. J Immunol Methods 2002; 264(1-2): 135-51. (Pubitemid 34615899)
176. Sorg RV, Ozcan Z, Brefort T, et al. Clinical-scale generation of dendritic cells in a closed system. J Immunother 2003; 26(4): 374-83. (Pubitemid 36858722)
177. Campbell JD, Piechaczek C, Winkels G, et al. Isolation and generation of clinical-grade dendritic cells using the CliniMACS system. Methods Mol Med 2005; 109: 55-70.
178. Barratt-Boyes SM, Zimmer MI, Harshyne LA, et al. Maturation and trafficking of monocyte-derived dendritic cells in monkeys: implications for dendritic cell-based vaccines. J Immunol 2000; 164(5): 2487-95. (Pubitemid 30115478)
179. Morse MA, Coleman RE, Akabani G, Niehaus N, Coleman D, Lyerly HK. Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res 1999; 59(1): 56-8. (Pubitemid 29062955)
180. Yu JS, Wheeler CJ, Zeltzer PM, et al. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 2001; 61(3): 842-7. (Pubitemid 32175145)
181. Yu JS, Liu G, Ying H, et al. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 2004; 64(14): 4973-9. (Pubitemid 38924545)
182. Liau LM, Prins RM, Kiertscher SM, et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res 2005; 11(15): 5515-25. (Pubitemid 41060828)
183. Rutkowski S, De Vleeschouwer S, Kaempgen E, et al. Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study. Br J Cancer 2004; 91(9): 1656-62. (Pubitemid 39546137)
184. Yamanaka R, Homma J, Yajima N, et al. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res 2005; 11(11): 4160-7. (Pubitemid 40791581)
185. Wheeler CJ, Black KL, Liu G, et al. Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res 2008; 68(14): 5955-64.
186. De Vleeschouwer S, Fieuws S, Rutkowski S, et al. Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res 2008; 14(10): 3098-104.
187. Boczkowski D, Nair SK, Nam JH, et al. Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res 2000; 60(4): 1028-34. (Pubitemid 30129541)
188. Boczkowski D, Nair SK, Snyder D, et al. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 1996; 184(2): 465-72. (Pubitemid 26324100)
189. Ashley DM, Faiola B, Nair S, et al. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med 1997; 186(7): 1177-82. (Pubitemid 27441162)
190. Nair SK, Boczkowski D, Morse M, et al. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat Biotechnol 1998; 16(4): 364-9. (Pubitemid 28164657)
191. Strobel I, Berchtold S, Gotze A, et al. Human dendritic cells transfected with either RNA or DNA encoding influenza matrix protein M1 differ in their ability to stimulate cytotoxic T lymphocytes. Gene Ther 2000; 7(23): 2028-35. (Pubitemid 32036769)
192. Caruso DA, Orme LM, Neale AM, et al. Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer. Neuro Oncol 2004; 6(3): 236-46. (Pubitemid 39136507)
193. Mackensen A, Herbst B, Chen JL, et al. Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells. Int J Cancer 2000; 86(3): 385-92. (Pubitemid 30187500)
194. Dannull J, Su Z, Rizzieri D, et al. Enhancement of vaccinemediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005; 115(12): 3623-33. (Pubitemid 43121851)
195. Su Z, Dannull J, Yang BK, et al. Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. J Immunol 2005; 174(6): 3798-807. (Pubitemid 40354093)
196. Kyte JA, Mu L, Aamdal S, et al. Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA. Cancer Gene Ther 2006; 13(10): 905-18. (Pubitemid 44373791)
197. Ludewig B, Ochsenbein AF, Odermatt B, et al. Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease. J Exp Med 2000; 191(5): 795-804.
198. Mitchell DA, Nair SK. RNA transfected dendritic cells as cancer vaccines. Curr Opin Mol Ther 2000; 2(2): 176-81. (Pubitemid 30212267)
199. Gilboa E, Nair SK, Lyerly HK. Immunotherapy of cancer with dendritic-cell-based vaccines. Cancer Immunol Immunother 1998; 46(2): 82-7. (Pubitemid 28177482)
200. Kumar V, Sercarz E. Genetic vaccination: the advantages of going naked. Nat Med. 1996; 2(8): 857-9. (Pubitemid 26296751)
201. Stevenson FK, Ottensmeier CH, Rice J. DNA vaccines against cancer come of age. Curr Opin Immunol. 2010; 22(2): 264-70.
202. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002; 20: 709-60. (Pubitemid 34293438)
203. Fioretti D, Iurescia S, Fazio VM, et al. DNA vaccines: developing new strategies against cancer. J Biomed Biotechnol 2010; 2010: 174378.
204. Nichols WW, Ledwith BJ, Manam SV, et al. Potential DNA vaccine integration into host cell genome. Ann N Y Acad Sci 1995; 772: 30-9. (Pubitemid 26080119)
205. Ledwith BJ, Manam S, Troilo PJ, et al. Plasmid DNA vaccines: assay for integration into host genomic DNA. Dev Biol (Basel) 2000; 104: 33-43.
206. De Marco F, Hallez S, Brulet JM, et al. DNA vaccines against HPV-16 E7-expressing tumour cells. Anticancer Res. 2003; 23(2B): 1449-54. (Pubitemid 36754113)
207. Michaluart P, Abdallah KA, Lima FD, et al. Phase I trial of DNA-hsp65 immunotherapy for advanced squamous cell carcinoma of the head and neck. Cancer Gene Ther 2008; 15(10): 676-84.
208. Victora GD, Socorro-Silva A, Volsi EC, et al. Immune response to vaccination with DNA-Hsp65 in a phase I clinical trial with head and neck cancer patients. Cancer Gene Ther. 2009; 16(7): 598-608.
209. Weber J, Boswell W, Smith J, et al. Phase 1 trial of intranodal injection of a Melan-A/MART-1 DNA plasmid vaccine in patients with stage IV melanoma. J Immunother 2008; 31(2): 215-23.
210. Cassaday RD, Sondel PM, King DM, et al. A phase I study of immunization using particle-mediated epidermal delivery of genes for gp100 and GM-CSF into uninvolved skin of melanoma patients. Clin Cancer Res 2007; 13(2 Pt 1): 540-9. (Pubitemid 46225360)
211. Gnjatic S, Altorki NK, Tang DN, et al. NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells. Clin Cancer Res 2009; 15(6): 2130-9.
212. O I, Blaszczyk-Thurin M, Shen CT, et al. A DNA vaccine expressing tyrosinase-related protein-2 induces T-cell-mediated protection against mouse glioblastoma. Cancer Gene Ther 2003; 10(9): 678-88. (Pubitemid 37138672)
213. Ramming KP, Pilch YH. Transfer of tumor-specific immunity with RNA: demonstration by immune cytolysis of tumor cells in vitro. J Natl Cancer Inst 1970; 45(3): 543-53.
214. Pilch YH, de Kernion JB, Skinner DG, et al. Immunotherapy of cancer with "immune" RNA. A preliminary report. Am J Surg 1976; 132(5): 631-7.
215. Pilch YH, Ramming KP, DeKernion JB. Preliminary studies of specific immunotherapy of cancer with immune RNA. Cancer 1977; 40(5 Suppl): 2747-57. (Pubitemid 8242487)
216. Bringmann A, Held SA, Heine A, et al. RNA vaccines in cancer treatment. J Biomed Biotechnol 2010; 2010: 623687.
217. Weide B, Carralot JP, Reese A, et al. Results of the first phase I/II clinical vaccination trial with direct injection of mRNA. J Immunother 2008; 31(2): 180-8.
218. Weide B, Pascolo S, Scheel B, et al. Direct injection of protamineprotected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients. J Immunother 2009; 32(5): 498-507.
219. Dubensky TW, Jr., Reed SG. Adjuvants for cancer vaccines. Semin Immunol 2010; 22(3): 155-61.
220. Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity 2010; 33(4): 492-503.
221. Lambrecht BN, Kool M, Willart MA, et al. Mechanism of action of clinically approved adjuvants. Curr Opin Immunol 2009; 21(1): 23-9.
222. Spreafico R, Ricciardi-Castagnoli P, Mortellaro A. The controversial relationship between NLRP3, alum, danger signals and the next-generation adjuvants. Eur J Immunol 2010; 40(3): 638-42.
223. Hollenbaugh JA, Dutton RW. IFN-gamma regulates donor CD8 T cell expansion, migration, and leads to apoptosis of cells of a solid tumor. J Immunol 2006; 177(5): 3004-11. (Pubitemid 44277816)
224. Hollenbaugh JA, Reome J, Dobrzanski M, et al. The rate of the CD8-dependent initial reduction in tumor volume is not limited by contact-dependent perforin, Fas ligand, or TNF-mediated cytolysis. J Immunol 2004; 173(3): 1738-43. (Pubitemid 38971605)
225. Dobrzanski MJ, Reome JB, Hollenbaugh JA, et al. Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses. J Immunol 2004; 172(3): 1380-90. (Pubitemid 38116779)
226. Aucouturier J, Dupuis L, Ganne V. Adjuvants designed for veterinary and human vaccines. Vaccine 2001; 19(17-19): 2666-72. (Pubitemid 32234287)
227. Spickler AR, Roth JA. Adjuvants in veterinary vaccines: modes of action and adverse effects. J Vet Intern Med 2003; 17(3): 273-81. (Pubitemid 37465326)
228. Aucouturier J, Dupuis L, Deville S, et al. Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines. Expert Rev Vaccines 2002; 1(1): 111-8. (Pubitemid 36686885)
229. Durando P, Icardi G, Ansaldi F. MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk. Expert Opin Biol Ther 2010; 10(4): 639-51.
230. El Sahly H. MF59™ as a vaccine adjuvant: a review of safety and immunogenicity. Expert Rev Vaccines 2010; 9(10): 1135-41.
231. Survivin Vaccine Therapy for Patients With Malignant Gliomas [database on the Internet]. U.S. National Institute of Health. 2010.
232. Jinushi M, Hodi FS, Dranoff G. Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines. Immunol Rev 2008; 222: 287-98. (Pubitemid 351430380)
233. Allione A, Consalvo M, Nanni P, et al. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor alpha, granulocytemacrophage colony-stimulating factor, and gamma-interferon gene or admixed with conventional adjuvants. Cancer Res 1994; 54(23): 6022-6.
234. Trinchieri G, Scott P. Interleukin-12: basic principles and clinical applications. Curr Top Microbiol Immunol 1999; 238: 57-78. (Pubitemid 29012971)
235. Pasquini S, Xiang Z, Wang Y, et al. Cytokines and costimulatory molecules as genetic adjuvants. Immunol Cell Biol 1997; 75(4): 397-401. (Pubitemid 27408048)
236. Berzofsky JA, Ahlers JD, Belyakov IM. Strategies for designing and optimizing new generation vaccines. Nat Rev Immunol 2001; 1(3): 209-19. (Pubitemid 33741959)
237. Clive KS, Tyler JA, Clifton GT, et al. Use of GM-CSF as an adjuvant with cancer vaccines: beneficial or detrimental? Expert Rev Vaccines 2010; 9(5): 519-25.
238. Sampson JH, Aldape KD, Archer GE, et al. Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro Oncol 2011; 13(3): 324-33.
239. Sampson JH, Heimberger AB, Archer GE, et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 2010; 28(31): 4722-9.
240. Johnson LA, Sampson JH. Immunotherapy approaches for malignant glioma from 2007 to 2009. Curr Neurol Neurosci Rep 2010; 10(4): 259-66.
241. O'Neill LA, Bowie AG. Sensing and signaling in antiviral innate immunity. Curr Biol 2010; 20(7): R328-33.
242. Nakhaei P, Genin P, Civas A, et al. RIG-I-like receptors: sensing and responding to RNA virus infection. Semin Immunol 2009; 21(4): 215-22.
243. Hennessy EJ, Parker AE, O'Neill LA. Targeting Toll-like receptors: emerging therapeutics? Nat Rev Drug Discov 2010; 9(4): 293-307.
244. Marrack P, McKee AS, Munks MW. Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol 2009; 9(4): 287-93.
245. Trinchieri G, Sher A. Cooperation of Toll-like receptor signals in innate immune defence. Nat Rev Immunol 2007; 7(3): 179-90.
246. Nicodemus CF, Berek JS. TLR3 agonists as immunotherapeutic agents. Immunotherapy 2010; 2(2): 137-40.
247. Prins RM, Soto H, Konkankit V, et al. Gene expression profile correlates with T cell infiltration and survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res 2011; 17(6): 1603-15.
248. Okada H, Kalinski P, Ueda R, et al. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol 2011; 29(3): 330-6.
249. Wells JW, Cowled CJ, Farzaneh F, et al. Combined triggering of dendritic cell receptors results in synergistic activation and potent cytotoxic immunity. J Immunol 2008; 181(5): 3422-31.
250. Ly LV, Sluijter M, Versluis M, et al. Peptide vaccination after Tcell transfer causes massive clonal expansion, tumor eradication, and manageable cytokine storm. Cancer Res 2010; 70(21): 8339-46.
251. Narayanan P, Lapteva N, Seethammagari M, Levitt JM, Slawin KM, Spencer DM. A composite MyD88/CD40 "switch" synergistically activates mouse and human dendritic cells for enhanced antitumor efficacy. J Clin Invest 2011; 121(4): 1524-34.
252. Duthie MS, Windish HP, Fox CB, et al. Use of defined TLR ligands as adjuvants within human vaccines. Immunol Rev 2011; 239(1): 178-96.
253. Zepp F. Principles of vaccine design-Lessons from nature. Vaccine 2010; 28 Suppl 3: C14-24.
254. Speck LM, Tyring SK. Vaccines for the prevention of human papillomavirus infections. Skin Therapy Lett 2006; 11(6): 1-3.
255. Didierlaurent AM, Morel S, Lockman L, et al. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol 2009; 183(10): 6186-97.
256. Kasturi SP, Skountzou I, Albrecht RA, et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 2011; 470(7335): 543-7.
257. Querec T, Bennouna S, Alkan S, et al. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J Exp Med 2006; 203(2): 413-24. (Pubitemid 43290850)
258. Khare V, Sodhi A, Singh SM. Age-dependent alterations in the tumoricidal functions of tumor-associated macrophages. Tumour Biol 1999; 20(1): 30-43. (Pubitemid 29009847)
259. Lu YF, Cerny J. Repertoire of antibody response in bone marrow and the memory response are differentially affected in aging mice. J Immunol 2002; 169(9): 4920-7. (Pubitemid 35217157)
260. Garcia GG, Miller RA. Age-dependent defects in TCR-triggered cytoskeletal rearrangement in CD4+ T cells. J Immunol 2002; 169(9): 5021-7. (Pubitemid 35217170)
261. Kapasi ZF, Murali-Krishna K, McRae ML, et al. Defective generation but normal maintenance of memory T cells in old mice. Eur J Immunol 2002; 32(6): 1567-73. (Pubitemid 34679145)
262. Elrefaei M, Blank KJ, Murasko DM. Decreased IL-2, IFN-gamma, and IL-10 production by aged mice during the acute phase of E55+ retrovirus infection. Virology 2002; 299(1): 8-19. (Pubitemid 35007506)
263. Provinciali M, Smorlesi A, Donnini A, et al. Low effectiveness of DNA vaccination against HER-2/neu in ageing. Vaccine 2003; 21(9-10): 843-8. (Pubitemid 36126417)
264. Finn OJ. Cancer vaccines: between the idea and the reality. Nat Rev Immunol 2003; 3(8): 630-41. (Pubitemid 37328666)
265. Wang D, Dubois RN. Prostaglandins and cancer. Gut 2006; 55(1): 115-22. (Pubitemid 41820645)
266. Sharma S, Yang SC, Zhu L, et al. Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer. Cancer Res 2005; 65(12): 5211-20. (Pubitemid 40827331)
267. Bodmer S, Strommer K, Frei K, et al. Immunosuppression and transforming growth factor-beta in glioblastoma. Preferential production of transforming growth factor-beta 2. J Immunol 1989; 143(10): 3222-9. (Pubitemid 20010149)
268. Constam DB, Philipp J, Malipiero UV, et al. Differential expression of transforming growth factor-beta 1, -beta 2, and -beta 3 by glioblastoma cells, astrocytes, and microglia. J Immunol 1992; 148(5): 1404-10.
269. Ranges GE, Figari IS, Espevik T, et al. Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha. J Exp Med 1987; 166(4): 991-8. (Pubitemid 18024241)
270. Gorelik L, Flavell RA. Abrogation of TGF-beta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity 2000; 12(2): 171-81. (Pubitemid 30398631)
271. Thomas DA, Massague J. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 2005; 8(5): 369-80. (Pubitemid 41579832)
272. Friese MA, Wischhusen J, Wick W, et al. RNA interference targeting transforming growth factor-beta enhances NKG2Dmediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo. Cancer Res 2004; 64(20): 7596-603. (Pubitemid 39372105)
273. Grutz G. New insights into the molecular mechanism of interleukin-10-mediated immunosuppression. J Leukocyte Biol 2005; 77(1): 3-15. (Pubitemid 40310687)
274. Hishii M, Nitta T, Ishida H, et al. Human glioma-derived interleukin-10 inhibits antitumor immune responses in vitro. Neurosurgery 1995; 37(6): 1160-6; discussion 6-7.
275. Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005; 6(4): 345-52. (Pubitemid 41716771)
276. Wang T, Niu G, Kortylewski M, et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 2004; 10(1): 48-54. (Pubitemid 38524698)
277. Konnikova L, Kotecki M, Kruger MM, et al. Knockdown of STAT3 expression by RNAi induces apoptosis in astrocytoma cells. BMC Cancer 2003; 3: 23.
278. Parekh K, Ramachandran S, Cooper J, et al. Tenascin-C, over expressed in lung cancer down regulates effector functions of tumor infiltrating lymphocytes. Lung Cancer 2005; 47(1): 17-29. (Pubitemid 39643238)
279. Fiore E, Fusco C, Romero P, et al. Matrix metalloproteinase 9 (MMP-9/gelatinase B) proteolytically cleaves ICAM-1 and participates in tumor cell resistance to natural killer cell-mediated cytotoxicity. Oncogene 2002; 21(34): 5213-23. (Pubitemid 34948133)
280. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000; 74: 181-273.
281. Meidenbauer N, Zippelius A, Pittet MJ, et al. High frequency of functionally active Melan-a-specific T cells in a patient with progressive immunoproteasome-deficient melanoma. Cancer Res 2004; 64(17): 6319-26. (Pubitemid 39129437)
282. Lohr J, Ratliff T, Huppertz A, et al. Effector T-cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumor-derived TGF-beta. Clin Cancer Res 2011; 17(13): 4296-308.
283. Wiendl H, Mitsdoerffer M, Hofmeister V, et al. A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape. J Immunol 2002; 168(9): 4772-80. (Pubitemid 34441386)
284. Seliger B, Maeurer MJ, Ferrone S. Antigen-processing machinery breakdown and tumor growth. Immunol Today 2000; 21(9): 455-64.
285. Hayashi T, Faustman DL. Development of spontaneous uterine tumors in low molecular mass polypeptide-2 knockout mice. Cancer Res 2002; 62(1): 24-7. (Pubitemid 34073979)
286. Gobbi G, Mirandola P, Micheloni C, et al. Expression of HLA class I antigen and proteasome subunits LMP-2 and LMP-10 in primary vs. metastatic breast carcinoma lesions. Int J Oncol 2004; 25(6): 1625-9.
287. Johnsen AK, Templeton DJ, Sy M, et al. Deficiency of transporter for antigen presentation (TAP) in tumor cells allows evasion of immune surveillance and increases tumorigenesis. J Immunol 1999; 163(8): 4224-31. (Pubitemid 29474486)
288. Ritz U, Momburg F, Pilch H, et al. Deficient expression of components of the MHC class I antigen processing machinery in human cervical carcinoma. Int J Oncol 2001; 19(6): 1211-20.
289. Cabrera CM, Jimenez P, Cabrera T, et al. Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways: beta2-microglobulin inactivation in MSI-positive tumors and LMP7/TAP2 downregulation in MSI-negative tumors. Tissue Antigens 2003; 61(3): 211-9. (Pubitemid 36605543)
290. Leithauser F, Dhein J, Mechtersheimer G, et al. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest 1993; 69(4): 415-29. (Pubitemid 23335841)
291. Roth W, Isenmann S, Nakamura M, et al. Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligandinduced apoptosis and chemotaxis. Cancer Res 2001; 61(6): 2759-65. (Pubitemid 32685866)
292. Wilmotte R, Burkhardt K, Kindler V, et al. B7-homolog 1 expression by human glioma: a new mechanism of immune evasion. Neuroreport 2005; 16(10): 1081-5. (Pubitemid 41017610)
293. Wintterle S, Schreiner B, Mitsdoerffer M, et al. Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. Cancer Res 2003; 63(21): 7462-7. (Pubitemid 37413489)
294. Parsa AT, Waldron JS, Panner A, et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 2007; 13(1): 84-8. (Pubitemid 46067390)
295. Sakaguchi S, Sakaguchi N, Asano M, et al. Immunologic selftolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of selftolerance causes various autoimmune diseases. J Immunol 1995; 155(3): 1151-64.
296. Misra N, Bayry J, Lacroix-Desmazes S, et al. Cutting edge: human CD4+CD25+ T cells restrain the maturation and antigen-presenting function of dendritic cells. J Immunol 2004; 172(8): 4676-80. (Pubitemid 38456386)
297. Fecci PE, Mitchell DA, Whitesides JF, et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res 2006; 66(6): 3294-302.
298. Jacobs JF, Idema AJ, Bol KF, et al. Prognostic significance and mechanism of Treg infiltration in human brain tumors. J Neuroimmunol 2010; 225(1-2): 195-9.
299. Heimberger AB, Abou-Ghazal M, Reina-Ortiz C, et al. Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas. Clin Cancer Res 2008; 14(16): 5166-72.
300. Liyanage UK, Moore TT, Joo HG, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002; 169(5): 2756-61. (Pubitemid 34921025)
301. Ghiringhelli F, Larmonier N, Schmitt E, et al. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 2004; 34(2): 336-44. (Pubitemid 39255944)
302. Colombo MP, Piconese S. Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat Rev Cancer 2007; 7(11): 880-7. (Pubitemid 350006256)